Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults

References

• Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am j med. 2008;121(4):258–264.
   PubMed Web of Science ®Google Scholar
• Buchy P, Selim B. Who and when to vaccinate against influenza. Inter J Infect Dis. 2020;93:375–387.
   PubMed Web of Science ®Google Scholar
• Manzoli L, Schioppa F, Boccia A, et al. The efficacy of influenza vaccine for healthy children. A meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J. 2007;26(2):97–106. doi: 10.1097/01.inf.0000253053.01151.bd
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in health children. Cochrane Database Syst Rev. 2008;2.
   Web of Science ®Google Scholar
• Negri E, Colombo C, Giordano L, et al. Influenza vaccine in healthy children: a meta-analysis. Vaccine. 2005;23(22):2851–2861. doi: 10.1016/j.vaccine.2004.11.053
   PubMed Web of Science ®Google Scholar
• Villari P, Manzoli L, Boccia A. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine. 2004;22(25–26):3475–3486. doi: 10.1016/j.vaccine.2004.01.068
   PubMed Web of Science ®Google Scholar
• Beyer WEP. Heterogeneity of case definitions used in vaccine effectiveness studies—and its impact on meta-analysis. Vaccine. 2006;24(44–46):6602–6604. doi: 10.1016/j.vaccine.2006.05.038
   PubMed Web of Science ®Google Scholar
• Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018;2.
   Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–1665. doi: 10.1001/jama.1994.03520210045030
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Internal Med. 1998;158(16):1769–1776.
   PubMedGoogle Scholar
• Sanyal M, Holmes TH, Maecker HT, et al. Diminished B-cell response after repeat influenza vaccination. J Infect Dis. 2019;219(10):1586–1595.
   PubMed Web of Science ®Google Scholar
• Khurana S, Hahn M, Coyle EM, et al. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nat Commun. 2019;10(1):1–15.
   PubMedGoogle Scholar
• Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019;17(1):1–16.
   PubMedGoogle Scholar
• Bartoszko JJ, McNamara IF, Aras OA, et al. Does consecutive influenza vaccination reduce protection against influenza: a systematic review and meta-analysis. Vaccine. 2018;36(24):3434–3444.
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263.
   PubMed Web of Science ®Google Scholar
• Krammer F, Fouchier RA, Eichelberger MC, et al. Naction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio. 2018;9(2):e02332–17.
   PubMed Web of Science ®Google Scholar
• Sangster S, Nguyen MYPQ, Topham DJ. Role of memory B cells in hemagglutinin-specific antibody production following human influenza a virus infection. Pathogens. 2019;8(4):167.
   PubMed Web of Science ®Google Scholar
• Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus res. 2004;103(1–2):133–138.
   PubMed Web of Science ®Google Scholar
• Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge university press; 2006.
   Google Scholar
• Khurana S, Verma N, Talaat KR, et al. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis. 2012;205(4):610–620. doi: 10.1093/infdis/jir791
   PubMed Web of Science ®Google Scholar
• Verma N, Dimitrova M, Carter DM, et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J Virol. 2012;86(10):5515–5522. doi: 10.1128/JVI.07085-11
   PubMed Web of Science ®Google Scholar
• Gouma S, Kim K, Weirick ME, et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat Commun. 2020;11(1):4566. doi: 10.1038/s41467-020-18465-x
   PubMed Web of Science ®Google Scholar
• Monto AS, Fukuda K. Lessons from influenza pandemics of the last 100 years. Clinl Infect Dis. 2020;70(5):951–957.
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667–671. doi: 10.1038/nature06890
   PubMed Web of Science ®Google Scholar
• Davis CW, Jackson KJ, McCausland MM, et al. Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination. Science. 2020;370(6513):237–241.
   PubMed Web of Science ®Google Scholar
• Nutt SL, Hodgkin PD, Tarlinton DM, et al. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15:160–171. doi: 10.1038/nri3795
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247(1):52–63. doi: 10.1111/j.1600-065X.2012.01124.x
   PubMed Web of Science ®Google Scholar
• Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6(10):741–750. doi: 10.1038/nri1886
   PubMed Web of Science ®Google Scholar
• MacLennan IC, Toellner K-M, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev. 2003;194(1):8–18. doi: 10.1034/j.1600-065X.2003.00058.x
   PubMed Web of Science ®Google Scholar
• Madsen A, Cox RJ. Prospects and challenges in the development of universal influenza vaccines. Vaccines. 2020;8(3):361.
   Web of Science ®Google Scholar
• Estrada LD, Schultz-Cherry S. Development of a universal influenza vaccine. J Immunol. 2019;202(2):392–398. doi: 10.4049/jimmunol.1801054
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Eisinger RW, et al. The pathway to a universal influenza vaccine. Immunity. 2017;47(4):599–603. doi: 10.1016/j.immuni.2017.09.007
   PubMed Web of Science ®Google Scholar
• Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64(1):189–202. doi: 10.1146/annurev-med-120611-145115
   PubMedGoogle Scholar
• Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza a vaccine. Vaccine. 2009;27(45):6280–6283. doi: 10.1016/j.vaccine.2009.07.007
   PubMed Web of Science ®Google Scholar
• Wei CJ, Crank MC, Shiver J, et al. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020;19(4):239–252.
   PubMed Web of Science ®Google Scholar
• Yuan L, Welsh JP, Swartz JR. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Nat Acad Sci. 2014;111(1):125–130.
   PubMed Web of Science ®Google Scholar
• Eichelberger MC, Monto AS. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J Infect Dis. 2019;219(Supplement_1):S75–S80.
   PubMedGoogle Scholar
• Mezhenskaya D, Isakova-Sivak I, Rudenko L. M2e-based universal influenza vaccines: a historical overview and new approaches to development. J Biomed Sci. 2019;26(1):1–15.
   PubMed Web of Science ®Google Scholar
• Hoskins TW, Davies J, Allchin A, et al. Controlled trial of inactivated influenza vaccine containing the A/Hong kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet. 1973;302(7821):116–120.
   Google Scholar
• Hoskins TW, JoanR Davies AJS, Allchin A, et al. Influenza at Christ’s hospital: March, 1974. Lancet. 1976;307(7951):105–108.
   Google Scholar
• Hoskins TW, Davies J, Smith AJ, et al. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza a at Christ’s hospital. Lancet. 1979;313(8106):33–35.
   Google Scholar
• Keitel WA, Cate TR, Couch RB, et al. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997;15(10):1114–1122.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Chambers C, De Serres G, et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during a (H3N2) epidemics in Canada, 2010–2011 to 2014–2015. J Infect Dis. 2017;215(7):1059–1099.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Forrest S, Ackley DH, et al. Variable efficacy of repeated annual influenza vaccination. Proc Nat Acad Sci. 1999;96(24):14001–14006.
   PubMed Web of Science ®Google Scholar
• Plant EP, Fredell LJ, Hatcher BA, et al. Different repeat annual influenza vaccinations improve the antibody response to drifted influenza strains. Sci Rep. 2017;7(1):1–12.
   PubMedGoogle Scholar
• Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007 Sep 28;25(39–40):6852–6862. doi: 10.1016/j.vaccine.2007.07.027
   PubMed Web of Science ®Google Scholar